APA (7th ed.) Citation

Zecca, C., Disanto, G., Sacco, R., Riccitelli, G. C., & Gobbi, C. (2019). Use of glatiramer acetate between 2010–2015: Effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients. BMC neurology, 19(1), 159-9. https://doi.org/10.1186/s12883-019-1383-6

Chicago Style (17th ed.) Citation

Zecca, Chiara, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli, and Claudio Gobbi. "Use of Glatiramer Acetate Between 2010–2015: Effectiveness, Safety and Reasons to Start GA as First or Second Line Treatment in Swiss Multiple Sclerosis Patients." BMC Neurology 19, no. 1 (2019): 159-9. https://doi.org/10.1186/s12883-019-1383-6.

MLA (9th ed.) Citation

Zecca, Chiara, et al. "Use of Glatiramer Acetate Between 2010–2015: Effectiveness, Safety and Reasons to Start GA as First or Second Line Treatment in Swiss Multiple Sclerosis Patients." BMC Neurology, vol. 19, no. 1, 2019, pp. 159-9, https://doi.org/10.1186/s12883-019-1383-6.